BriaCell Therapeutics Corp. (BCTX)

CA — Healthcare Sector
Peers: ALZN  BCTXW  CNTX  DATS  GRTX  MREO  PDSB  VRPX  XFOR 

Automate Your Wheel Strategy on BCTX

With Tiblio's Option Bot, you can configure your own wheel strategy including BCTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BCTX
  • Rev/Share 0.0
  • Book/Share 3.1967
  • PB 0.2243
  • Debt/Equity 0.0
  • CurrentRatio 3.4141
  • ROIC -1.9271

 

  • MktCap 13086100.0
  • FreeCF/Share -6.4446
  • PFCF -0.5436
  • PE -0.1433
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -4.3974

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BriaCell Awarded New Zealand Patent for its Whole Cell Technology
BCTX
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces that it has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. The patent covers methods of selecting its whole-cell cancer immunotherapy technology for subjects with cancer based on HLA allele profile matching, providing exclusivity through February 27, 2037, and supporting BriaCell's precision medicine approach aimed at personalizing immunotherapy for improved patient outcomes.

Read More
image for news BriaCell Awarded New Zealand Patent for its Whole Cell Technology
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
BCTX
Published: July 15, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit is being sold to the public at a price of $1.25 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $15 million, before deducting placement agent …

Read More
image for news BriaCell Therapeutics Announces Pricing of $15 million Public Offering
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
BCTX
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical data in three clinical poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. BriaCell has featured robust survival and clinical benefit data from its Bria-IMT Phase 2 clinical study, clinical progress data from its ongoing pivotal Bria-IMT Phase 3 study (ClinicalTrials.gov identifier: NCT06072612), and Phase 1/2 study of Bria-OTS (ClinicalTrials.gov identifier: NCT06471673) in metastatic …

Read More
image for news BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
BCTX
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA and VANCOUVER, British Columbia, May 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the presentation of positive survival and clinical benefit data in three clinical poster presentations and one publish-only abstract at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL.

Read More
image for news BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
BCTX
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patients Presence of Circulating Tumor Cells (CTC) after patients' initial Phase 3 treatment supports role as negative prognostic marker (p = 0.04) Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile PHILADELPHIA and VANCOUVER, British Columbia, April 30, 2025 …

Read More
image for news BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
BCTX
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting positive data from its Phase 2 study of lead product candidate, Bria-IMT™, in metastatic breast cancer, and from its preclinical Bria-OTS+ platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. In addition, Phase 3 early biomarker data will be presented as a late breaking abstract.

Read More
image for news BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
BCTX
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

Over 75 patients enrolled in BriaCell's pivotal Phase 3 study of Bria-IMT ™ plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is …

Read More
image for news BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
BCTX
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR.

Read More
image for news BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer
BCTX
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be halted, has completed its second safety data review of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer (NCT06072612) and recommended …

Read More
image for news Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

About BriaCell Therapeutics Corp. (BCTX)

  • IPO Date 2012-03-14
  • Website https://www.briacell.com
  • Industry Biotechnology
  • CEO William V. Williams FCPA,
  • Employees 16

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.